189 related articles for article (PubMed ID: 30359928)
1. Understanding the use of diverted buprenorphine.
Cicero TJ; Ellis MS; Chilcoat HD
Drug Alcohol Depend; 2018 Dec; 193():117-123. PubMed ID: 30359928
[TBL] [Abstract][Full Text] [Related]
2. Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.
Smith KE; Tillson MD; Staton M; Winston EM
Drug Alcohol Depend; 2020 Mar; 208():107837. PubMed ID: 31951906
[TBL] [Abstract][Full Text] [Related]
3. Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
Chilcoat HD; Amick HR; Sherwood MR; Dunn KE
J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System.
Wiegand TJ; Le Lait MC; Bartelson BB; Dart RC; Green JL
J Pain; 2016 Jun; 17(6):745-52. PubMed ID: 26996928
[TBL] [Abstract][Full Text] [Related]
5. The More Things Change: Buprenorphine/naloxone Diversion Continues While Treatment Remains Inaccessible.
Carroll JJ; Rich JD; Green TC
J Addict Med; 2018; 12(6):459-465. PubMed ID: 30095563
[TBL] [Abstract][Full Text] [Related]
6. Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.
Adams JW; Duprey M; Khan S; Cance J; Rice DP; Bobashev G
Harm Reduct J; 2023 Oct; 20(1):150. PubMed ID: 37848945
[TBL] [Abstract][Full Text] [Related]
7. Non-Prescribed Buprenorphine in New York City: Motivations for Use, Practices of Diversion, and Experiences of Stigma.
Allen B; Harocopos A
J Subst Abuse Treat; 2016 Nov; 70():81-86. PubMed ID: 27692193
[TBL] [Abstract][Full Text] [Related]
8. How Motivations for Using Buprenorphine Products Differ From Using Opioid Analgesics: Evidence from an Observational Study of Internet Discussions Among Recreational Users.
Butler SF; Oyedele NK; Dailey Govoni T; Green JL
JMIR Public Health Surveill; 2020 Mar; 6(1):e16038. PubMed ID: 32209533
[TBL] [Abstract][Full Text] [Related]
9. Scope of, Motivations for, and Outcomes Associated with Buprenorphine Diversion in the United States: A Scoping Review.
Rubel SK; Eisenstat M; Wolff J; Calevski M; Mital S
Subst Use Misuse; 2023; 58(5):685-697. PubMed ID: 36803159
[TBL] [Abstract][Full Text] [Related]
10. On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.
Silverstein SM; Daniulaityte R; Miller SC; Martins SS; Carlson RG
Drug Alcohol Depend; 2020 May; 210():107958. PubMed ID: 32203863
[TBL] [Abstract][Full Text] [Related]
11. Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?
Doernberg M; Krawczyk N; Agus D; Fingerhood M
Subst Abus; 2019; 40(2):148-153. PubMed ID: 31008694
[TBL] [Abstract][Full Text] [Related]
12. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.
Bazazi AR; Yokell M; Fu JJ; Rich JD; Zaller ND
J Addict Med; 2011 Sep; 5(3):175-80. PubMed ID: 21844833
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine use and setting type among reproductive-aged women self-reporting nonmedical prescription opioid use.
DeSisto CL; Terplan M; Kacha-Ochana A; Green JL; Mueller T; Cox S; Ko JY
J Subst Use Addict Treat; 2023 Dec; 155():209083. PubMed ID: 37245854
[TBL] [Abstract][Full Text] [Related]
14. Increasing rates of buprenorphine diversion in the United States, 2002 to 2019.
Buttram ME; Kurtz SP; Margolin ZR; Severtson SG
Pharmacoepidemiol Drug Saf; 2021 Nov; 30(11):1514-1519. PubMed ID: 34302707
[TBL] [Abstract][Full Text] [Related]
15. Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors.
Johnson B; Richert T
Int J Drug Policy; 2015 Feb; 26(2):183-90. PubMed ID: 25465344
[TBL] [Abstract][Full Text] [Related]
16. Buprenorphine prescribing practice trends and attitudes among New York providers.
Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
[TBL] [Abstract][Full Text] [Related]
17. Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural Physicians.
Andrilla CHA; Moore TE; Patterson DG
J Rural Health; 2019 Jan; 35(1):113-121. PubMed ID: 30339720
[TBL] [Abstract][Full Text] [Related]
18. Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US.
Han B; Jones CM; Einstein EB; Compton WM
JAMA Netw Open; 2021 Oct; 4(10):e2129409. PubMed ID: 34652446
[TBL] [Abstract][Full Text] [Related]
19. Comparative prices of diverted buprenorphine/naloxone and buprenorphine in a UK prison setting: a cross-sectional survey of drug using prisoners.
Wright NM; Mohammed Z; Hughes GJ
Drug Alcohol Depend; 2014 Nov; 144():254-8. PubMed ID: 25305714
[TBL] [Abstract][Full Text] [Related]
20. Assessing Motivations for Nonprescribed Buprenorphine Use Among Rural Appalachian Substance Users.
McDonald MJ; DeVeaugh-Geiss AM; Chilcoat HD; Havens JR
J Addict Med; 2023 Jan-Feb 01; 17(1):95-100. PubMed ID: 36044288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
